Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRGX NASDAQ:QURE NASDAQ:SNDX NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRGXCARGO Therapeutics$4.49+0.4%$4.42$3.00▼$25.45$206.11M0.283.18 million shs673,476 shsQUREuniQure$13.69-1.7%$14.83$4.45▼$19.18$763.75M0.111.32 million shs1.06 million shsSNDXSyndax Pharmaceuticals$9.98+0.6%$9.88$8.58▼$22.50$853.59M0.741.75 million shs1.73 million shsTRVITrevi Therapeutics$7.33-1.1%$6.47$2.36▼$8.11$868.55M0.581.77 million shs1.58 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRGXCARGO Therapeutics+0.45%-0.66%+2.05%+3.94%-73.63%QUREuniQure-1.65%-9.40%-4.13%-7.31%+78.72%SNDXSyndax Pharmaceuticals+0.60%+3.63%+10.89%-27.31%-56.04%TRVITrevi Therapeutics-1.08%-6.86%+22.58%+4.86%+130.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRGXCARGO Therapeutics2.0303 of 5 stars2.90.00.00.01.91.71.3QUREuniQure2.4186 of 5 stars3.52.00.00.01.82.50.6SNDXSyndax Pharmaceuticals3.5579 of 5 stars3.51.00.04.43.20.80.0TRVITrevi Therapeutics2.4543 of 5 stars4.71.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRGXCARGO Therapeutics 1.86Reduce$15.40242.98% UpsideQUREuniQure 2.91Moderate Buy$36.55166.95% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$34.10241.68% UpsideTRVITrevi Therapeutics 3.30Buy$20.88184.79% UpsideCurrent Analyst Ratings BreakdownLatest CRGX, QURE, SNDX, and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$47.007/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$38.00 ➝ $35.007/15/2025SNDXSyndax PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$37.00 ➝ $35.007/10/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.007/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.007/1/2025TRVITrevi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.006/2/2025TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/2/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.005/30/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.005/29/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.005/28/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$21.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRGXCARGO TherapeuticsN/AN/AN/AN/A$7.83 per shareN/AQUREuniQure$27.12M27.70N/AN/A($0.07) per share-195.57SNDXSyndax Pharmaceuticals$23.68M36.27N/AN/A$3.38 per share2.95TRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRGXCARGO Therapeutics-$167.50M-$4.62N/AN/AN/AN/A-45.93%-39.58%8/11/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%N/ASNDXSyndax Pharmaceuticals-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.45N/AN/AN/AN/A-58.41%-52.52%8/7/2025 (Estimated)Latest CRGX, QURE, SNDX, and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRGXCARGO Therapeutics-$0.42N/AN/AN/AN/AN/A8/7/2025Q2 2025SNDXSyndax Pharmaceuticals-$0.99N/AN/AN/AN/AN/A8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10N/AN/AN/AN/AN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 million5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/A5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRGXCARGO TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRGXCARGO TherapeuticsN/A6.306.30QUREuniQure1.539.9811.99SNDXSyndax Pharmaceuticals1.535.805.75TRVITrevi TherapeuticsN/A15.3815.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRGXCARGO Therapeutics93.16%QUREuniQure78.83%SNDXSyndax PharmaceuticalsN/ATRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipCRGXCARGO Therapeutics2.92%QUREuniQure4.79%SNDXSyndax Pharmaceuticals4.10%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRGXCARGO Therapeutics11646.11 million44.76 millionN/AQUREuniQure50054.87 million52.24 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableTRVITrevi Therapeutics20117.29 million95.83 millionOptionableCRGX, QURE, SNDX, and TRVI HeadlinesRecent News About These CompaniesTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 0.1% - Here's What HappenedAugust 1 at 3:50 AM | marketbeat.comTrevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025July 31 at 4:05 PM | prnewswire.comTrevi Therapeutics to Participate in Upcoming August ConferencesJuly 29, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Time to Buy?July 24, 2025 | marketbeat.comWall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should KnowJuly 11, 2025 | zacks.comTrevi Therapeutics (NASDAQ:TRVI) Trading 6.1% Higher - Time to Buy?July 9, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading Down 3.7% - Should You Sell?July 3, 2025 | marketbeat.comAnalysts Offer Predictions for TRVI FY2025 EarningsJuly 3, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationJuly 2, 2025 | msn.comTRVI Trevi Therapeutics, Inc. - Seeking AlphaJuly 1, 2025 | seekingalpha.comTrevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 1, 2025 | prnewswire.comTRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the FirmJune 26, 2025 | globenewswire.comTRVI - Trevi Therapeutics Inc Key Metrics - MorningstarJune 24, 2025 | morningstar.comMTrevi Therapeutics Stockholders Approve Key AmendmentsJune 17, 2025 | tipranks.comTrevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 5, 2025 | prnewswire.comTrevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockJune 3, 2025 | prnewswire.comTrevi Therapeutics Announces Proposed Public Offering of Common StockJune 2, 2025 | prnewswire.comTrevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease PatientsJune 2, 2025 | benzinga.comTrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 2, 2025 | prnewswire.comTrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 1, 2025 | prnewswire.comH.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy RatingMay 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRGX, QURE, SNDX, and TRVI Company DescriptionsCARGO Therapeutics NASDAQ:CRGX$4.49 +0.02 (+0.45%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.44 -0.04 (-1.00%) As of 08/1/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.uniQure NASDAQ:QURE$13.69 -0.23 (-1.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.21 +0.52 (+3.80%) As of 08/1/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Syndax Pharmaceuticals NASDAQ:SNDX$9.98 +0.06 (+0.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.12 +0.14 (+1.35%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Trevi Therapeutics NASDAQ:TRVI$7.33 -0.08 (-1.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.40 +0.07 (+0.94%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
